• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.82% Nasdaq Up0.70%

    More On QPT.V

    Quotes

    Charts

    News & Info

    Company

    Analyst Coverage

    • Analyst Opinion
    • Analyst Estimates

    Ownership

    • Major Holders
    • Insider Transactions
    • Insider Roster

    Financials


    Quest PharmaTech, Inc. (QPT.V)

    -TSXV
    0.06 Up 0.01(9.09%) 3:58PM EDT
    ProfileGet Profile for:
    Quest PharmaTech, Inc.
    8123 Roper Road NW
    Edmonton, AB T6E 6S4
    Canada - Map
    Phone: 780-448-1400
    Fax: 780-416-0324
    Website: http://www.questpharmatech.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:N/A

    Business Summary 

    Quest PharmaTech Inc., a biotechnology company, develops and commercializes oncology products in Asia. The company operates through two segments, Biopharmaceutical/Pharmaceutical Products and Cosmetic Products. It develops a portfolio of product candidates for the treatment of cancer by combining immunotherapeutic antibodies with chemotherapy, photodynamic therapy, or immune-adjuvants. The company’s lead product candidate is Oregovomab, an immunotherapeutic product for the treatment of ovarian cancer, which is under Phase IIb clinical trial in Italy and the United States. It also develops anti-MUC1 antibody for the treatment of pancreatic cancer; Anti-HER2/neu IgE, which is in preclinical trial for the treatment of solid malignancy; and SL052, an injectable formulation for the treatment of prostate cancer. In addition, the company markets and distributes Bellus Skin, an anti-wrinkle skin care product. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Quest PharmaTech, Inc.

    Key Executives 
     PayExercised
    Dr. Ragupathy Madiyalakan Ph.D.,
    Chief Exec. Officer, Director, Member of Audit Committee, Member of Compensation Committee and Member of Corp. Governance Committee
    160.00K0.00
    Mr. Pierre Vermette C.A.,
    Chief Financial Officer
    105.00K0.00
    Mr. Thomas Woo M.Sc.,
    VP of Product Devel.
    131.00K0.00
    Mr. Roger Andrews ,
    Head of Investor Relations & Corp. Communications
    N/AN/A
    Mr. Douglas C. Bachman , 62
    VP of Corp. Devel.
    N/AN/A
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in CAD.